<p>随着美国股市在人工智能泡沫担忧和主要指数波动的挑战环境中航行，投资者密切关注就业数据和零售销售等关键经济指标，以评估未来趋势。在这种环境下，拥有强大内部持股的成长型公司可以提供独特的吸引力，因为高比例的内部持股通常表明对公司长期前景的信心，尽管市场波动较大。</p>
<h3>美国内部持股比例高的十大成长型公司</h3>
<table>
<thead>
<tr>
<th></th>
<th></th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>名称</strong></td>
<td><strong>内部持股</strong></td>
<td><strong>收益增长</strong></td>
</tr>
<tr>
<td>超微计算机 (SMCI)</td>
<td>13.9%</td>
<td>50.7%</td>
</tr>
<tr>
<td>StubHub Holdings (STUB)</td>
<td>14.2%</td>
<td>73.9%</td>
</tr>
<tr>
<td>SES AI (SES)</td>
<td>12%</td>
<td>68.9%</td>
</tr>
<tr>
<td>Niu Technologies (NIU)</td>
<td>37.2%</td>
<td>93.7%</td>
</tr>
<tr>
<td>Karman Holdings (KRMN)</td>
<td>17.3%</td>
<td>78.5%</td>
</tr>
<tr>
<td>Credo Technology Group Holding (CRDO)</td>
<td>10.4%</td>
<td>30.7%</td>
</tr>
<tr>
<td>Bitdeer Technologies Group (BTDR)</td>
<td>33.4%</td>
<td>133.2%</td>
</tr>
<tr>
<td>Atour Lifestyle Holdings (ATAT)</td>
<td>18%</td>
<td>24.4%</td>
</tr>
<tr>
<td>Astera Labs (ALAB)</td>
<td>11.7%</td>
<td>29.0%</td>
</tr>
<tr>
<td>AppLovin (APP)</td>
<td>27.4%</td>
<td>27.1%</td>
</tr>
</tbody>
</table>
<p>点击这里查看我们筛选的 204 只内部持股比例高的快速成长美国公司的完整名单。</p>
<p>让我们更仔细地看看我们从筛选公司中挑选的几家公司。</p>
<h2>Bridgewater Bancshares (BWB)</h2>
<p><strong>Simply Wall St 成长评级：</strong> ★★★★☆☆</p>
<p><strong>概述：</strong> Bridgewater Bancshares, Inc. 是 Bridgewater Bank 的银行控股公司，在美国提供一系列银行产品和服务，市值为 5.1749 亿美元。</p>
<p><strong>运营：</strong> 公司的收入主要来自其银行业务部门，产生了 1.2724 亿美元的收入。</p>
<p><strong>内部持股：</strong> 20.5%</p>
<p><strong>收益增长预测：</strong> 每年 22%。</p>
<p>Bridgewater Bancshares 展示了增长潜力，预计收益每年增长 22%，超过美国市场的平均水平。然而，内部持股动态显示最近购买的股份多于出售的股份，表明尽管过去一个季度没有实质性购买，但仍然对公司充满信心。该公司交易价格显著低于估计的公允价值，预计年收入增长为 14.4%。最近的领导层变动可能会增强信贷策略，并支持在商业贷款领域的进一步扩展。</p>
<ul>
<li>在我们的收益增长报告中更详细地了解 Bridgewater Bancshares 的潜力。</li>
<li>我们最近的估值报告指出，Bridgewater Bancshares 的股票在市场上可能被低估。</li>
</ul>
<p><img src="https://imageproxy.pbkrs.com/https://images.simplywall.st/company/49c54dff-423c-4c2d-8fc1-01efaa0a244d/chart/ownership-breakdown?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" original-src="https://imageproxy.pbkrs.com/https://images.simplywall.st/company/49c54dff-423c-4c2d-8fc1-01efaa0a244d/chart/ownership-breakdown"/></p>
<p>截至 2025 年 12 月的 BWB 持股分布</p>
<h2>Aebi Schmidt Holding (AEBI)</h2>
<p><strong>Simply Wall St 成长评级：</strong> ★★★★★☆</p>
<p><strong>概述：</strong> Aebi Schmidt Holding AG 开发和制造特种车辆及附件，市值为 10.4 亿美元。</p>
<p><strong>运营：</strong> 公司的收入主要来自北美，贡献了 7.8105 亿美元，欧洲及其他地区贡献了 5.1543 亿美元。</p>
<p><strong>内部持股：</strong> 14.2%</p>
<p><strong>收益增长预测：</strong> 每年 148.1%。</p>
<p>Aebi Schmidt Holding 正在经历显著增长，预计收益每年增长 148.1%，超过美国市场。内部活动显示过去三个月有大量购买，表明对其发展轨迹的信心。尽管交易价格低于估计公允价值 62%，且强劲的收入增长预测为 29.3%，但最近的财务数据显示，与去年相比，利润率和净收入下降，表明在快速扩张过程中维持盈利能力面临挑战。</p>
<ul>
<li>点击这里了解 Aebi Schmidt Holding 的细微差别，查看我们的详细分析未来增长报告。</li>
<li>我们精心准备的 Aebi Schmidt Holding 估值报告暗示其股价可能过高。</li>
</ul>
<p><img src="https://imageproxy.pbkrs.com/https://images.simplywall.st/company/9ad44c93-884f-42b4-b627-e0de80a5b732/chart/ownership-breakdown?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" original-src="https://imageproxy.pbkrs.com/https://images.simplywall.st/company/9ad44c93-884f-42b4-b627-e0de80a5b732/chart/ownership-breakdown"/></p>
<p>截至 2025 年 12 月的 AEBI 持股分布</p>
<h2>Precigen (PGEN)</h2>
<p><strong>Simply Wall St 成长评级：</strong> ★★★★★☆</p>
<p><strong>概述：</strong> Precigen, Inc. 是一家发现和临床阶段的生物制药公司，专注于开发用于免疫肿瘤学、自身免疫疾病和传染病的基因和细胞疗法，市值为 13.5 亿美元。</p>
<p><strong>运营：</strong> 公司的收入部门专注于开发先进的基因和细胞疗法，旨在治疗免疫肿瘤学、自身免疫疾病和传染病。</p>
<p><strong>内部持股：</strong> 12.3%</p>
<p><strong>收益增长预测：</strong> 每年 79.7%。</p>
<p>Precigen 的收入预计每年增长 55.8%，显著超过美国市场，同时计划在三年内实现盈利。尽管最近内部出售和高股价波动，PAPZIMEOS™ 的 FDA 批准标志着在治疗复发性呼吸道乳头状瘤病方面的重大进展。然而，最近的财务数据显示，尽管收入增长，净亏损却有所增加，突显在扩张和创新努力中实现盈利的持续挑战。</p>
<ul>
<li>通过阅读我们的分析师估计报告，深入了解 Precigen 的表现。</li>
<li>在审查我们最新的估值报告后，Precigen 的股价可能过于乐观。</li>
</ul>
<p><img src="https://imageproxy.pbkrs.com/https://images.simplywall.st/company/0fb7141f-fd80-4e2e-93e9-552be9c67d53/chart/earnings-and-revenue-growth?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" original-src="https://imageproxy.pbkrs.com/https://images.simplywall.st/company/0fb7141f-fd80-4e2e-93e9-552be9c67d53/chart/earnings-and-revenue-growth"/></p>
<p>截至 2025 年 12 月的 PGEN 收益和收入增长</p>
<h2>总结</h2>
<ul>
<li>在这里探索我们筛选的 204 个内部持股比例高的快速成长美国公司。</li>
<li>准备好进入其他投资风格了吗？人工智能即将改变医疗保健。这 30 只股票正在从早期诊断到药物发现方面进行工作。最重要的是——它们的市值都在 100 亿美元以下——仍然有机会提前布局。</li>
</ul>
<p>这篇来自 Simply Wall St 的文章是一般性的。<strong>我们仅基于历史数据和分析师预测提供评论，采用无偏见的方法，我们的文章并不意图作为财务建议。</strong> 它不构成买卖任何股票的推荐，也未考虑您的目标或财务状况。我们的目标是为您提供以基本数据驱动的长期分析。请注意，我们的分析可能未考虑最新的价格敏感公司公告或定性材料。Simply Wall St 在提到的任何股票中没有持仓。该分析仅考虑内部人士直接持有的股票，不包括通过其他工具如公司和/或信托实体间接持有的股票。所有预测的收入和收益增长率均以年化（每年）增长率的形式表示，时间范围为 1-3 年。</p>
<p>国防与灾难的移动基础设施</p>
<p>下一波机器人技术不是类人机器人，而是能够在 30 分钟内在任何地方提供 5G、ISR 和雷达的完全自主塔。</p>
<p>在下一轮合同之前获取投资者简报</p>
<p>由 CiTech 赞助</p>

<p>这篇文章强调了具有强大内部持股的成长股，重点关注了 Bridgewater Bancshares、Aebi Schmidt Holding 和 Precigen。这些公司显示出有前景的盈利增长预测，内部活动表明对其发展轨迹的信心。尽管市场波动，这些股票因其增长前景和内部持股而具有潜在价值。该分析基于历史数据和预测，并非财务建议</p>

<p>As the U.S. stock market navigates a challenging landscape marked by AI bubble concerns and fluctuating major indexes, investors are keenly observing key economic indicators like employment data and retail sales to gauge future trends. In this environment, growth companies with strong insider ownership can offer a unique appeal, as high insider stakes often signal confidence in the company's long-term prospects despite broader market volatility.</p>
<div class="lb-trans"><p>随着美国股市在人工智能泡沫担忧和主要指数波动的挑战环境中航行，投资者密切关注就业数据和零售销售等关键经济指标，以评估未来趋势。在这种环境下，拥有强大内部持股的成长型公司可以提供独特的吸引力，因为高比例的内部持股通常表明对公司长期前景的信心，尽管市场波动较大。</p>
</div><h3>Top 10 Growth Companies With High Insider Ownership In The United States</h3>
<div class="lb-trans"><h3>美国内部持股比例高的十大成长型公司</h3>
</div><table>
<thead>
<tr>
<th></th>
<th></th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Name</strong></td>
<td><strong>Insider Ownership</strong></td>
<td><strong>Earnings Growth</strong></td>
</tr>
<tr>
<td>Super Micro Computer (SMCI)</td>
<td>13.9%</td>
<td>50.7%</td>
</tr>
<tr>
<td>StubHub Holdings (STUB)</td>
<td>14.2%</td>
<td>73.9%</td>
</tr>
<tr>
<td>SES AI (SES)</td>
<td>12%</td>
<td>68.9%</td>
</tr>
<tr>
<td>Niu Technologies (NIU)</td>
<td>37.2%</td>
<td>93.7%</td>
</tr>
<tr>
<td>Karman Holdings (KRMN)</td>
<td>17.3%</td>
<td>78.5%</td>
</tr>
<tr>
<td>Credo Technology Group Holding (CRDO)</td>
<td>10.4%</td>
<td>30.7%</td>
</tr>
<tr>
<td>Bitdeer Technologies Group (BTDR)</td>
<td>33.4%</td>
<td>133.2%</td>
</tr>
<tr>
<td>Atour Lifestyle Holdings (ATAT)</td>
<td>18%</td>
<td>24.4%</td>
</tr>
<tr>
<td>Astera Labs (ALAB)</td>
<td>11.7%</td>
<td>29.0%</td>
</tr>
<tr>
<td>AppLovin (APP)</td>
<td>27.4%</td>
<td>27.1%</td>
</tr>
</tbody>
</table>
<div class="lb-trans"><table>
<thead>
<tr>
<th></th>
<th></th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>名称</strong></td>
<td><strong>内部持股</strong></td>
<td><strong>收益增长</strong></td>
</tr>
<tr>
<td>超微计算机 (SMCI)</td>
<td>13.9%</td>
<td>50.7%</td>
</tr>
<tr>
<td>StubHub Holdings (STUB)</td>
<td>14.2%</td>
<td>73.9%</td>
</tr>
<tr>
<td>SES AI (SES)</td>
<td>12%</td>
<td>68.9%</td>
</tr>
<tr>
<td>Niu Technologies (NIU)</td>
<td>37.2%</td>
<td>93.7%</td>
</tr>
<tr>
<td>Karman Holdings (KRMN)</td>
<td>17.3%</td>
<td>78.5%</td>
</tr>
<tr>
<td>Credo Technology Group Holding (CRDO)</td>
<td>10.4%</td>
<td>30.7%</td>
</tr>
<tr>
<td>Bitdeer Technologies Group (BTDR)</td>
<td>33.4%</td>
<td>133.2%</td>
</tr>
<tr>
<td>Atour Lifestyle Holdings (ATAT)</td>
<td>18%</td>
<td>24.4%</td>
</tr>
<tr>
<td>Astera Labs (ALAB)</td>
<td>11.7%</td>
<td>29.0%</td>
</tr>
<tr>
<td>AppLovin (APP)</td>
<td>27.4%</td>
<td>27.1%</td>
</tr>
</tbody>
</table>
</div><p>Click here to see the full list of 204 stocks from our Fast Growing US Companies With High Insider Ownership screener.</p>
<div class="lb-trans"><p>点击这里查看我们筛选的 204 只内部持股比例高的快速成长美国公司的完整名单。</p>
</div><p>Let's take a closer look at a couple of our picks from the screened companies.</p>
<div class="lb-trans"><p>让我们更仔细地看看我们从筛选公司中挑选的几家公司。</p>
</div><h2>Bridgewater Bancshares (BWB)</h2>
<div class="lb-trans"><h2>Bridgewater Bancshares (BWB)</h2>
</div><p><strong>Simply Wall St Growth Rating:</strong> ★★★★☆☆</p>
<div class="lb-trans"><p><strong>Simply Wall St 成长评级：</strong> ★★★★☆☆</p>
</div><p><strong>Overview:</strong> Bridgewater Bancshares, Inc. is the bank holding company for Bridgewater Bank, offering a range of banking products and services in the United States with a market cap of $517.49 million.</p>
<div class="lb-trans"><p><strong>概述：</strong> Bridgewater Bancshares, Inc. 是 Bridgewater Bank 的银行控股公司，在美国提供一系列银行产品和服务，市值为 5.1749 亿美元。</p>
</div><p><strong>Operations:</strong> The company's revenue is primarily derived from its banking segment, which generated $127.24 million.</p>
<div class="lb-trans"><p><strong>运营：</strong> 公司的收入主要来自其银行业务部门，产生了 1.2724 亿美元的收入。</p>
</div><p><strong>Insider Ownership:</strong> 20.5%</p>
<div class="lb-trans"><p><strong>内部持股：</strong> 20.5%</p>
</div><p><strong>Earnings Growth Forecast:</strong> 22% p.a.</p>
<div class="lb-trans"><p><strong>收益增长预测：</strong> 每年 22%。</p>
</div><p>Bridgewater Bancshares demonstrates growth potential with its earnings forecast to grow 22% annually, surpassing the US market's average. However, insider ownership dynamics show more shares were bought than sold recently, indicating confidence despite no substantial buying in the past quarter. The company trades at a significant discount to estimated fair value and expects revenue growth of 14.4% annually. Recent leadership changes could bolster credit strategies and support further expansion in commercial lending sectors.</p>
<div class="lb-trans"><p>Bridgewater Bancshares 展示了增长潜力，预计收益每年增长 22%，超过美国市场的平均水平。然而，内部持股动态显示最近购买的股份多于出售的股份，表明尽管过去一个季度没有实质性购买，但仍然对公司充满信心。该公司交易价格显著低于估计的公允价值，预计年收入增长为 14.4%。最近的领导层变动可能会增强信贷策略，并支持在商业贷款领域的进一步扩展。</p>
</div><ul>
<li>Take a closer look at Bridgewater Bancshares' potential here in our earnings growth report.</li>
<li>Insights from our recent valuation report point to the potential undervaluation of Bridgewater Bancshares shares in the market.</li>
</ul>
<div class="lb-trans"><ul>
<li>在我们的收益增长报告中更详细地了解 Bridgewater Bancshares 的潜力。</li>
<li>我们最近的估值报告指出，Bridgewater Bancshares 的股票在市场上可能被低估。</li>
</ul>
</div><p><img src="https://imageproxy.pbkrs.com/https://images.simplywall.st/company/49c54dff-423c-4c2d-8fc1-01efaa0a244d/chart/ownership-breakdown" alt="" original-src="https://images.simplywall.st/company/49c54dff-423c-4c2d-8fc1-01efaa0a244d/chart/ownership-breakdown"/></p>
<p>BWB Ownership Breakdown as at Dec 2025</p>
<div class="lb-trans"><p>截至 2025 年 12 月的 BWB 持股分布</p>
</div><h2>Aebi Schmidt Holding (AEBI)</h2>
<div class="lb-trans"><h2>Aebi Schmidt Holding (AEBI)</h2>
</div><p><strong>Simply Wall St Growth Rating:</strong> ★★★★★☆</p>
<div class="lb-trans"><p><strong>Simply Wall St 成长评级：</strong> ★★★★★☆</p>
</div><p><strong>Overview:</strong> Aebi Schmidt Holding AG develops and manufactures special-purpose vehicles and attachments, with a market cap of $1.04 billion.</p>
<div class="lb-trans"><p><strong>概述：</strong> Aebi Schmidt Holding AG 开发和制造特种车辆及附件，市值为 10.4 亿美元。</p>
</div><p><strong>Operations:</strong> The company's revenue is primarily derived from North America, contributing $781.05 million, and Europe and the Rest of the World, accounting for $515.43 million.</p>
<div class="lb-trans"><p><strong>运营：</strong> 公司的收入主要来自北美，贡献了 7.8105 亿美元，欧洲及其他地区贡献了 5.1543 亿美元。</p>
</div><p><strong>Insider Ownership:</strong> 14.2%</p>
<div class="lb-trans"><p><strong>内部持股：</strong> 14.2%</p>
</div><p><strong>Earnings Growth Forecast:</strong> 148.1% p.a.</p>
<div class="lb-trans"><p><strong>收益增长预测：</strong> 每年 148.1%。</p>
</div><p>Aebi Schmidt Holding is experiencing significant growth with earnings forecast to rise 148.1% annually, outpacing the US market. Insider activity shows substantial buying over the past three months, signaling confidence in its trajectory. Despite trading at 62% below estimated fair value and strong revenue growth projections of 29.3%, recent financials reveal declining profit margins and net income compared to last year, suggesting challenges in maintaining profitability amidst rapid expansion efforts.</p>
<div class="lb-trans"><p>Aebi Schmidt Holding 正在经历显著增长，预计收益每年增长 148.1%，超过美国市场。内部活动显示过去三个月有大量购买，表明对其发展轨迹的信心。尽管交易价格低于估计公允价值 62%，且强劲的收入增长预测为 29.3%，但最近的财务数据显示，与去年相比，利润率和净收入下降，表明在快速扩张过程中维持盈利能力面临挑战。</p>
</div><ul>
<li>Click here to discover the nuances of Aebi Schmidt Holding with our detailed analytical future growth report.</li>
<li>Our expertly prepared valuation report Aebi Schmidt Holding implies its share price may be too high.</li>
</ul>
<div class="lb-trans"><ul>
<li>点击这里了解 Aebi Schmidt Holding 的细微差别，查看我们的详细分析未来增长报告。</li>
<li>我们精心准备的 Aebi Schmidt Holding 估值报告暗示其股价可能过高。</li>
</ul>
</div><p><img src="https://imageproxy.pbkrs.com/https://images.simplywall.st/company/9ad44c93-884f-42b4-b627-e0de80a5b732/chart/ownership-breakdown" alt="" original-src="https://images.simplywall.st/company/9ad44c93-884f-42b4-b627-e0de80a5b732/chart/ownership-breakdown"/></p>
<p>AEBI Ownership Breakdown as at Dec 2025</p>
<div class="lb-trans"><p>截至 2025 年 12 月的 AEBI 持股分布</p>
</div><h2>Precigen (PGEN)</h2>
<div class="lb-trans"><h2>Precigen (PGEN)</h2>
</div><p><strong>Simply Wall St Growth Rating:</strong> ★★★★★☆</p>
<div class="lb-trans"><p><strong>Simply Wall St 成长评级：</strong> ★★★★★☆</p>
</div><p><strong>Overview:</strong> Precigen, Inc. is a discovery and clinical-stage biopharmaceutical company focused on developing gene and cell therapies for immuno-oncology, autoimmune disorders, and infectious diseases, with a market cap of $1.35 billion.</p>
<div class="lb-trans"><p><strong>概述：</strong> Precigen, Inc. 是一家发现和临床阶段的生物制药公司，专注于开发用于免疫肿瘤学、自身免疫疾病和传染病的基因和细胞疗法，市值为 13.5 亿美元。</p>
</div><p><strong>Operations:</strong> The company's revenue segments focus on developing advanced gene and cell therapies aimed at treating conditions in immuno-oncology, autoimmune disorders, and infectious diseases.</p>
<div class="lb-trans"><p><strong>运营：</strong> 公司的收入部门专注于开发先进的基因和细胞疗法，旨在治疗免疫肿瘤学、自身免疫疾病和传染病。</p>
</div><p><strong>Insider Ownership:</strong> 12.3%</p>
<div class="lb-trans"><p><strong>内部持股：</strong> 12.3%</p>
</div><p><strong>Earnings Growth Forecast:</strong> 79.7% p.a.</p>
<div class="lb-trans"><p><strong>收益增长预测：</strong> 每年 79.7%。</p>
</div><p>Precigen's revenue is forecast to grow 55.8% annually, significantly outpacing the US market, while it aims for profitability within three years. Despite recent insider selling and high share price volatility, the FDA approval of PAPZIMEOS™ marks a pivotal advancement in treating recurrent respiratory papillomatosis. However, recent financials show increased net losses despite revenue growth, highlighting ongoing challenges in achieving profitability amidst its expansion and innovation efforts.</p>
<div class="lb-trans"><p>Precigen 的收入预计每年增长 55.8%，显著超过美国市场，同时计划在三年内实现盈利。尽管最近内部出售和高股价波动，PAPZIMEOS™ 的 FDA 批准标志着在治疗复发性呼吸道乳头状瘤病方面的重大进展。然而，最近的财务数据显示，尽管收入增长，净亏损却有所增加，突显在扩张和创新努力中实现盈利的持续挑战。</p>
</div><ul>
<li>Get an in-depth perspective on Precigen's performance by reading our analyst estimates report here.</li>
<li>Upon reviewing our latest valuation report, Precigen's share price might be too optimistic.</li>
</ul>
<div class="lb-trans"><ul>
<li>通过阅读我们的分析师估计报告，深入了解 Precigen 的表现。</li>
<li>在审查我们最新的估值报告后，Precigen 的股价可能过于乐观。</li>
</ul>
</div><p><img src="https://imageproxy.pbkrs.com/https://images.simplywall.st/company/0fb7141f-fd80-4e2e-93e9-552be9c67d53/chart/earnings-and-revenue-growth" alt="" original-src="https://images.simplywall.st/company/0fb7141f-fd80-4e2e-93e9-552be9c67d53/chart/earnings-and-revenue-growth"/></p>
<p>PGEN Earnings and Revenue Growth as at Dec 2025</p>
<div class="lb-trans"><p>截至 2025 年 12 月的 PGEN 收益和收入增长</p>
</div><h2>Summing It All Up</h2>
<div class="lb-trans"><h2>总结</h2>
</div><ul>
<li>Explore the 204 names from our Fast Growing US Companies With High Insider Ownership screener here.</li>
<li>Ready To Venture Into Other Investment Styles? AI is about to change healthcare. These 30 stocks are working on everything from early diagnostics to drug discovery. The best part - they are all under $10b in market cap - there's still time to get in early.</li>
</ul>
<div class="lb-trans"><ul>
<li>在这里探索我们筛选的 204 个内部持股比例高的快速成长美国公司。</li>
<li>准备好进入其他投资风格了吗？人工智能即将改变医疗保健。这 30 只股票正在从早期诊断到药物发现方面进行工作。最重要的是——它们的市值都在 100 亿美元以下——仍然有机会提前布局。</li>
</ul>
</div><p><em>This article by Simply Wall St is general in nature. <strong>We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice.</strong> It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.The analysis only considers stock directly held by insiders. It does not include indirectly owned stock through other vehicles such as corporate and/or trust entities. All forecast revenue and earnings growth rates quoted are in terms of annualised (per annum) growth rates over 1-3 years.</em></p>
<div class="lb-trans"><p>这篇来自 Simply Wall St 的文章是一般性的。<strong>我们仅基于历史数据和分析师预测提供评论，采用无偏见的方法，我们的文章并不意图作为财务建议。</strong> 它不构成买卖任何股票的推荐，也未考虑您的目标或财务状况。我们的目标是为您提供以基本数据驱动的长期分析。请注意，我们的分析可能未考虑最新的价格敏感公司公告或定性材料。Simply Wall St 在提到的任何股票中没有持仓。该分析仅考虑内部人士直接持有的股票，不包括通过其他工具如公司和/或信托实体间接持有的股票。所有预测的收入和收益增长率均以年化（每年）增长率的形式表示，时间范围为 1-3 年。</p>
</div><p>Mobile Infrastructure for Defense and Disaster</p>
<div class="lb-trans"><p>国防与灾难的移动基础设施</p>
</div><p>The next wave in robotics isn't humanoid. Its fully autonomous towers delivering 5G, ISR, and radar in under 30 minutes, anywhere.</p>
<div class="lb-trans"><p>下一波机器人技术不是类人机器人，而是能够在 30 分钟内在任何地方提供 5G、ISR 和雷达的完全自主塔。</p>
</div><p>Get the investor briefing before the next round of contracts</p>
<div class="lb-trans"><p>在下一轮合同之前获取投资者简报</p>
</div><p>Sponsored On Behalf of CiTech</p>
<div class="lb-trans"><p>由 CiTech 赞助</p>
</div>

聚焦 Bridgewater Bancshares 及其他两只内部持股强劲的成长型股票